Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues

Table 3

BRAF annotation.

Variation type	Mutation effect	Oncogenic	Tumor	Drug
N581S	Gain-of-function	Oncogene	None	None
V600 E K601Q	Gain-of-function	Oncogene	None	None
D594 G	Gain-of-function	Oncogene	None	None
R260 C	None	None	None	None
K601 N	Gain-of-function	Oncogene	None	None
V600 E	Gain-of-function	Oncogene	Nonsmall cell lung cancer	Dabrafenib + trametinib
			Anaplastic	Vemurafenib
			Thyroid cancer melanoma	Dabrafenib
			Colorectal cancer	Vemurafenib + cobimetinib
			Hairy cell Leukemia	Trametinib
				Encorafenib + binimetinib
				Encorafenib + binimetinib + cetuximab
				Panitumumab + dabrafenib + trametinib
L597Q	Gain-of-function	Oncogene	None	None
V600 G	Gain-of-function	Oncogene	None	None
D594 N	Gain-of-function	Oncogene	None	None
Gene rearrangement	None	None	None	None
Splice sites change	None	None	None	None
G466 A	Gain-of-function	Oncogene	None	None